Gilead Sciences wants to make sure its anti-viral drug remdesivir, which has proven effective in treating patients afflicted with Covid-19, is available to all.
In an open letter, CEO Daniel O’Day on Monday said Gilead will provide remdesivir “well below” the value that it has so far proven to provide in treating patients afflicted with Covid-19, the respiratory illness contracted through exposure to the novel coronavirus.
“In normal circumstances, we would price a medicine according to the value it provides,” O’Day said in the letter. However, “To ensure broad and equitable access at a time of urgent global need, we have set a price for governments of developed countries of $390 per vial.”
Based on current treatment patterns, the vast majority of patients are expected to receive a 5-day treatment course using six vials of remdesivir, which equates to $2,340 per patient, O’Day said.
Remdesivir is a broad-spectrum antiviral medication administered via injection that has proven effective at helping patients with severe symptoms of Covid-19 recover. While Gilead has received emergency use authorization from the Food and Drug Administration, it has not yet been formally approved as a coronavirus treatment.
Watch More Videos From TheStreet and Jim Cramer:
- Coronavirus Update: Gilead's Remdesivir Will Cost $2,340 for 5 Day Treatment
- June 29, 2007: Apple Releases the iPhone, Transforming Much of the Modern World
- Is it Legal For New York, New Jersey and Connecticut to Mandate a Quarantine?
- What Jim Cramer's Watching Ahead of July 4
- Jim Cramer: McCormick Is a 'Story of Cooking at Home'
- Jim Cramer: Advice for Investors Learning About the Stock Market
- TheStreet Explains: What is Day Trading and How Has it Impacted Stocks?
- TheStreet Explains: Why Are Investors Calling For More Fiscal Policy?